NewAmsterdam Pharma Company N.V. (NAMS) Revenue History
Annual and quarterly revenue from 2020 to present
NAMS Revenue Over Time (2020–2025)
NAMS Revenue Growth History
1 of 3 years with positive growth- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- -86.3%
- FY2024 revenue growth
- +223.4%
- FY2025 revenue growth
- -50.6%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $3.0M | +2.1% |
| Q4 2025 | $32K | -99.7% |
| Q3 2025 | $348K | -98.8% |
| Q2 2025 | $19.1M | +740.1% |
| Q1 2025 | $3.0M | +112.6% |
| Q4 2024 | $12.8M | +1490.5% |
| Q3 2024 | $29.1M | — |
| Q2 2024 | $2.3M | +32.7% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2022)
NAMS's revenue distribution by segment and geography for fiscal year 2022
By Product/Segment
NAMS Revenue Analysis (2020–2025)
Current Revenue & Growth
As of July 8, 2026, NewAmsterdam Pharma Company N.V. (NAMS) generated trailing twelve-month (TTM) revenue of $22.6 million, reflecting modest growth of +2.1% year-over-year. The most recent quarter (Q1 2026) recorded $3.0 million in revenue, up 9400.0% sequentially.
Historical Growth Trajectory
NAMS's historical revenue data shows a 3-year CAGR of -39.7%. NewAmsterdam Pharma Company N.V.'s highest annual revenue of $102.7 million was recorded in 2022.
Revenue by Segment
NAMS's revenue is primarily driven by License Revenue (100%). With over half of revenue concentrated in License Revenue, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including ESPR (+61.1% YoY), MDGL (+256.8% YoY), and LNTH (+0.6% YoY) — NAMS has underperformed the peer group in revenue growth. Compare NAMS vs ESPR →
NAMS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| NAMSCurrent | $23M | +2.1% | - | -1002.9% | |
 ESPR | $403M | +61.1% | +12.1% | 15.0% | |
 MDGL | $958M | +256.8% | - | -31.3% | |
 LNTH | $1.5B | +0.6% | +35.3% | 20.2% | |
 PFE | $62.6B | +1.4% | +8.5% | 24.7% | |
 MRK | $64.9B | +2.5% | +9.4% | 36.2% |
NAMS Historical Revenue Data (2020–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $22.5M | -50.6% | $22.4M | 99.7% | $-225,683,000 | -1002.9% |
| 2024 | $45.6M | +223.4% | $45.6M | 100.0% | $-176,289,000 | -386.9% |
| 2023 | $14.1M | -86.3% | $14.1M | 100.0% | $-182,967,000 | -1298.6% |
| 2022 | $102.7M | - | $102.7M | 100.0% | $-3,557,000 | -3.5% |
| 2021 | $0 | - | $0 | - | $-34,977,000 | - |
| 2020 | $0 | - | $0 | - | $-6,632,054 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
6+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NAMS — Frequently Asked Questions
Quick answers to the most common questions about buying NAMS stock.
Is NAMS's revenue growth accelerating or slowing?
NAMS revenue growth is slowing. TTM revenue is $23M, up +2.1% year-over-year — below the 5-year CAGR of N/A. The deceleration suggests maturing end-markets or increased competition.
What is NAMS's revenue history from 2020 to 2026?
NewAmsterdam Pharma Company N.V. (NAMS) revenue history spans 2020 to 2026. TTM revenue as of 2026 is $23M, growing at +2.1% YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is NAMS's long-term revenue growth rate (CAGR)?
NewAmsterdam Pharma Company N.V.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of +2.1% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for NAMS.
Why does NAMS's quarterly revenue fluctuate?
NAMS quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. NewAmsterdam Pharma Company N.V.'s revenue data from 2020 to 2026 shows full historical quarterly detail on this page.
How is NAMS's revenue distributed by segment?
NAMS reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does NAMS's revenue compare to industry peers?
NewAmsterdam Pharma Company N.V. (NAMS) with TTM revenue of $23M and +2.1% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.